Alnylam Pharmaceuticals, Inc.ALNY

Is ALNY cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$258.00-2.10 (-0.81%)24:00 UTC
NASDAQHealthcare

Company snapshot

Market Cap
$36B
Large-cap
+438%
2016 — today
10-Year Price
+233%
2016 — today
52-Week Range
$205.48$491.22
Current $258.00· 18%

Alnylam Pharmaceuticals discovers, develops, and commercializes RNA interference (RNAi) therapeutics. Its portfolio includes approved treatments ONPATTRO (hereditary transthyretin-mediated amyloidosis), GIVLAARI (acute hepatic porphyria), and OXLUMO (primary hyperoxaluria type 1). The pipeline targets genetic, cardio-metabolic, hepatic, CNS, and ocular disorders, with candidates like zilebesiran, fitusiran, and vutrisiran. Based in Cambridge, MA, Alnylam partners with Regeneron, Sanofi, Novartis, and others.

Featured in rankings

Rankings recomputed after each US market close — see where ALNY stands against peers.

Similar companies

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
43.6
Near historic high
Near historic highs — last 10 years
Sector median 25.0above sector
P/B ratio
26.3
Above average
Pricier than usual over the last 10 years
Sector median 2.5above sector
EV / EBITDA
30.6
Near historic low
Near historic low — last 10 years
Sector median 15.3above sector
FCF Yield
1.5%
Near historic high
Near historic highs — last 10 years
Sector median -9.6%above sector
Free · No credit card needed

Get alerted when ALNY is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.